Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | GLI1 | P08151 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381046 | 1.00 | PTGS2 (0.74) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL5499383 | 0.88 | PTGS2 (0.63) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL16830125 | 0.87 | PTGS2 (0.70) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL13109321 | 0.85 | PTGS2 (0.64) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL6375235 | 0.83 | PTGS2 (0.87) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL5605782 | 0.83 | PTGS2 (0.87) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL29938771 | 0.83 | PTGS2 (0.87) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL5604980 | 0.83 | PTGS2 (0.87) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL5604953 | 0.82 | PTGS2 (0.85) | PTGS2PTGS1MAPTCXCR1CXCR2 | |
| SCHEMBL13730902 | 0.82 | PTGS2 (0.93) | PTGS2PTGS1MAPTCXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | claimed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | claimed |
| EP-1526839-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | Nicox S.A. (FR) | 2005-05-04 | — | — | EP | claimed |
| WO-2004000273-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | claimed |
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | disclosed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1492543-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | Nicox S.A. (FR) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084550-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | NICOX S.A. (FR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | ABCG2, SLCO1B1, SLCO4C1 | PTGS2 653/4885PTGS1 515/4885MAPT 1241/4885 |
| US-20070010458-A1 | Drugs for the arthritis treatment | PTGS1, ADORA2B, PTGS2 | PTGS2 3/4885PTGS1 1/4885MAPT 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.